Artisan Partners Limited Partnership Sells 111,721 Shares of LivaNova PLC $LIVN

Artisan Partners Limited Partnership lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 4.6% during the fourth quarter, HoldingsChannel reports. The firm owned 2,315,324 shares of the company’s stock after selling 111,721 shares during the period. Artisan Partners Limited Partnership’s holdings in LivaNova were worth $142,462,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Hantz Financial Services Inc. raised its holdings in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. State of Wyoming bought a new stake in shares of LivaNova in the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC raised its holdings in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Quarry LP bought a new stake in shares of LivaNova in the 3rd quarter worth approximately $36,000. Finally, Covestor Ltd raised its holdings in shares of LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after purchasing an additional 392 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LIVN shares. Mizuho lifted their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Robert W. Baird lowered their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC lifted their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Barclays lifted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Stock Down 0.3%

LivaNova stock opened at $79.48 on Wednesday. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $80.96. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of 40.76 and a beta of 0.88. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The firm has a 50 day simple moving average of $69.71 and a 200 day simple moving average of $66.04.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same period in the previous year, the business earned $0.88 EPS. LivaNova’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts predict that LivaNova PLC will post 3.73 earnings per share for the current year.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.35% of the stock is owned by company insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.